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Background. Trials on assessing the benefits of EGFR inhibitors in head and neck squamous cell carcinoma (HNSCC) patients have
gradually been published. Nevertheless, the benefits of gefitinib in advanced HNSCC are still unknown. Methods. The Cochrane
library, PubMed, and EMBASE databases were systematically searched from the inception dates to 17 July 2017, 18 July 2017, and 19
July 2017, respectively. The keywords “head and neck” and gefitinib were used to retrieve in articles and abstracts. An additional
search for recently published randomized trials was performed from July 17, 2017, to April 18, 2018. Then we assessed the risk of
bias of the included studies based on the Cochrane “Risk of Bias” tool. Quantitative analysis was carried out to evaluate the overall
survival (OS), progression free survival (PFS), overall response rate (ORR), and grade 3-4 adverse effects by ReviewManager 5.0.2
and the quality-of-life was analyzed in the included studies. Results. Seven randomized controlled trials and a total number of 1287
patients were involved. There were no significant differences in OS, PFS, or ORR between gefitinib and no gefitinib group (HR 1.07,
95% CI 0.93 to 1.22, and P=0.35; HR 0.84, 95% CI 0.69 to 1.04, and P=0.11; RR 1.04, 95% CI 0.90 to 1.20, and P =0.60, respectively).
However, gefitinib alone was equivalent to chemotherapeutics (i.e., methotrexate; methotrexate + fluorouracil) in ORR in patients
with recurrent HNSCC, and a trend of improvement in QOL in gefitinib group was showed. Toxicities revealed no differences
except for diarrhea and skin toxicity (p=0.0003; p=0.03, respectively). Conclusion. For patients with advanced HNSCC, gefitinib
cannot prolong the OS and PFS or improve ORR, and odds of skin toxicity and diarrhea increased. However, gefitinib alone is
equivalent to methotrexate or methotrexate + fluorouracil and tends to improve QOL for recurrent patients.
1. Introduction
Head and neck cancer is one of the leading causes of cancer
deaths in the world. Squamous cell carcinoma and its variants
account formore than 90% of these tumors [1], involving can-
cers of lip, oral cavity, pharynx, larynx, and paranasal sinuses.
It is estimated that about 300,400 new cases and 145,400
deaths from lip cancer and oral cavity cancer occurred in
2012 worldwide [2], and approximately 63,030 new oral
cavity, pharynx, and larynx cancer cases and 13,360 deaths
occurred in the United States during 2017 [3]. For decades,
oral cavity cancer incidence rates have decreased in Asia,
Northern America, and Australia. However, with the ongoing
tobacco epidemic, the rates increased in several countries of
Eastern and Northern Europe and among females in South-
ern and Western Europe [2]. Approximately two-thirds of
head and neck squamous cell carcinomas (HNSCCs) present
in advanced stage, including local stage (stage III/IVa/IVb)
and metastatic stage (stage IVc) [4]. Surgery cannot achieve
satisfactory results due to limitations of gender, age, and
health status. A concomitant or alternating systemic therapy
is used for treatment, whichwas limited by the high incidence
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of resistance, lack of specificity, and unacceptable adverse
effects of radiotherapy and chemotherapy. Over the past
years, the incidence of local recurrence and distant metastasis
has increased, and the survival benefit of HNSCC has
reached the bottleneck stage. Drugs with high efficiency, high
selectivity, low toxicity, and reverse resistance of radiotherapy
and chemotherapy are badly needed. EGFR is a member of
a family of receptor tyrosine kinases, which was expressed
in the majority of epithelial malignancies including breast,
glioblastoma, and squamous cell carcinoma [5]. According
to Ang et al. [6], 95% of the HNSCCs had detectable EGFR
expression, and more than 90% were overexpressed. Com-
pared to lower EGFR-expressing HNSCCs patients, these
with higher EGFR-expressing had significantly poorer overall
survival (OS) and disease-free survival (DFS) and lower local-
regional control (LRC).There are two major classes of EGFR-
targeted drugs: the extracellular domain of the receptor
monoclonal antibody (MAb) and the acting on the recep-
tor intracellular region of small molecule tyrosine kinase
inhibitors (TKIs). It is now well established from a variety
of studies [7, 8] that, for patients with HNSCCs, cetuximab
confers a statistically significant improvement in OS, which
was approved by the U.S. Food and Drug Administration
(FDA) in 2006 to treat HNSCC [9]. One of the other types
of EGFR-blocking drug known as TKI, gefitinib is effective in
the treatment of lung cancer with EGFR mutations; however,
its benefits in HNSCCs are unknown. Trials on assessing
the benefits of gefitinib in HNSCCs patients have recently
been published. Therefore, a meta-analysis was performed to
clarify the effectiveness and safety of gefitinib for advanced
head and neck squamous cell carcinoma. To be specific, since
the prognosis of metastatic HNSCC is very similar to that of
recurrent HNSCC, advanced HNSCC is often divided into
locoregionally advanced (LA) stage and recurrent/metastatic
(RM) stage [4].Therefore, the “advanced disease” of HNSCC
in the current study includes both LA stage and RM stage.
2. Methods
2.1. Search Methods. We searched the Cochrane Central
Register of Controlled Trials (CENTRAL), the Cochrane
Library on 17 July 2017; PubMed databases on 18 July 2017;
Embase databases on 19 July 2017. The keywords “head
and neck” and gefitinib were used to retrieve in articles
and abstracts. In addition, we searched the reference lists
of included trials and contacted experts in the field. An
additional search was performed from July 17, 2017, to April
18, 2018, to identify recently published RCTs of those meeting
the inclusion criteria, using the databases and keywords
described above.
2.2. Inclusion Criteria. Randomized controlled trials were
included based on the following inclusion criteria: (1) written
in English, (2) involving patients diagnosed with biopsy-
proven HNSCC, and (3) the studies that reported hazard
ratios (HRs) for OS or progression-free survival (PFS) or
both, response rate or grade 3-4 adverse drug reactions. At
the same time, studies were excluded based on the following
criteria: (1) Trials for nasopharynx cancer or esophageal
cancer were excluded because these cancers differ from other
head and neck cancers in etiology, epidemiology, histological
type, and therapeutic schedules [10]. (2) Studies whose full
text cannot be obtained were excluded as well.
2.3. Risk-of-BiasAssessments. Themethodological quality for
all included RCTs was evaluated according to Cochrane risk-
of-bias criteria, including the randomization sequence gener-
ation, allocation concealment, blinding, incomplete outcome
data, selective reporting, and other biases. And each quality
item was graded as low risk, high risk, or unclear risk.
2.4. Data Extraction. The following information as well as
the experiment data from all obtained studies were extracted:
the author’s name, publication year, gender, country, number
of patients, mean age, therapy regimens, the hazard ratio
(HR) and 95% CI of either overall survival (OS) and/or PFS,
overall response rate(ORR), quality-of-life (QOL), and grade
3-4 adverse effect.
2.5. Statistical Analysis. We performed meta-analysis to cal-
culate the overall HR and its 95% CI for OS and PFS.
Relative risk (RR) and its 95% CI were calculated for ORR
and grade 3-4 toxicities. A statistical test with p<0.05 is
considered a significant outcome, while a P value >0.05
indicates no significant difference between the two com-
parison arms. Standard Q test and I2 statistic were used to
estimate statistical heterogeneity among trials. Heterogeneity
exists in the pooled HRs or RRs when P values<0.10 or
I2 >50% [11]. When homogeneity is deemed invalid (p<0.10,
I2 >50%), a random-effect model is applied for secondary
analysis; otherwise, a fixed-effect model was used. The meta-
analyseswere performed usingReviewManagerVersion 5.0.2
(the Cochrane collaboration). Potential publication bias was
evaluated by Begg’s funnel plot and Egger’s tests, which were
performed using STATA version 12.0 (STATA Corp, College
Station, TX). And P < 0.05 represents significant publication
bias.
3. Results
3.1. Eligible Studies and Characteristics. First, we identified
365 potentially eligible records in the initial search and
obtained 346 records after deduplication. Thenwe selected 20
reports from them for further evaluation after screening their
titles and abstracts. Finally, we obtained seven records [12–18]
whichmeet the inclusion criteria for our study (Figure 1).The
7 selected papers were published between 2009 and 2016 and
involved a total number of 1287 patients. Table 1 reports the
characteristics of the included RCTs.
3.2. Risk of Bias in Included Studies. The included studies for
risk of bias were assessed based on the Cochrane “Risk of
Bias” tool. Results of the overall “Risk of Bias” assessment
are displayed in Figure 2(a) and a summary of the risk of
bias for each included trial was displayed in Figure 2(b). All
included studies stated that they were “randomized.” Three
trials [12, 13, 15] described an adequate random sequence gen-
eration process only, and one trial [16] performed imbalanced
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365 Records identified through database 
searching
PubMed: n = 91
EMBase: n =142
Cochrane Library: n=132
19 Duplicate studies excluded
346 Unique records
identified
326 Records excluded
on title or abstract basis
20 Results included for 
further evaluation
Excluded:
4 not meeting inclusion criteria
9 Lack of sufficient information
7 Eligible RCTs
Figure 1: Literature search and screening process.
randomization. Allocation was adequately concealed in two
studies [12, 16], and the remaining five studies did not report
the method of allocation concealment. Three trials [12, 15, 16]
were double blind, while one trial [13] allocation was open-
label; the other trials were unclear. Four articles [12, 13, 16, 17]
have reported complete outcome data, and the other three
articles [14, 15, 18] explicitly provided the number and reasons
for withdrawal or loss to follow-up. In three of the included
papers [12, 13, 15], the protocol is available. Others are not,
which were judged the risk of reporting bias as unclear.
One study [16] with imbalanced baseline characteristics was
performed at their institute, so it was left as high risk of bias
for this domain.
3.3. Overall Survival (OS). Four records were included in this
meta-analysis, which reported the hazard ratios (HR) and
their 95% CIs for OS. There were no significant differences
in OS between gefitinib and no gefitinib group (HR 1.07, 95%
CI 0.93 to 1.22, and P=0.35; Figure 3).
3.4. Progression-Free Survival (PFS). On the basis of the three
studies that reported the hazard ratios (HR) and their 95%
CIs for PFS, no significant differences were found between
patients with gefitinib and no gefitinib (HR 0.84, 95%CI 0.69
to 1.04, and P=0.11; Figure 4).
3.5. Overall Response Rate (ORR). All the seven reports had
data on ORR, and the RR analysis revealed no advantage
for gefitinib-based treatment (Figure 5(a)) in patients with
advanced head and neck cancer (RR 1.04, 95%CI 0.90 to 1.20,
and P = 0.60).
Moreover, we conduct subgroup analyses of the effec-
tiveness of gefitinib in patients with recurrent squamous
cell carcinoma of the head and neck. The results from two
studies indicated that they are equivalent in ORR (RR 1.29,
95% CI 0.60 to 2.78, and P = 0.51; Figure 5(b)) between
gefitinib alone and chemotherapeutics, such as methotrexate
and methotrexate + fluorouracil.
3.6. Quality-of-Life (QOL). QOL was analyzed in three of
the included studies, which involved recurrent HNSCC
patients. Kushwaha et al. [14] measured QOL with the
instrument FHNSI-10 only. Stewart et al. [13] assessed QOL
combining FHNSI-10 with the FACTH&N questionnaires.
Bhattacharya et al. evaluated the QOL using the EORTC
QLQ-C30 (version 3.0) and the QLQ-H and N35 instruments
[18]. Due to the different evaluation methods, data cannot
be derived. Therefore, descriptive analysis was carried out.
Stewart et al. [13] demonstrated a trend of improvement
in QOL measures in patients randomly assigned to gefi-
tinib, although these improvements were not statistically
significant. The results of Bhattacharya suggested that gefi-
tinib group has a better QOL than the control group in
locally advanced HNSCC [18], but they did not conduct
statistical analysis of the results. Kushwaha’s result that
demonstrated significant improvements in QOL with man-
ageable toxicities was observed in gefitinib arm (P<0.001)
[14].
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Figure 2: Risk of bias. (a) Risk of bias graph based on the Cochrane “Risk of bias” tool. (b) Risk of bias summary based on the Cochrane
“Risk of bias” tool.
3.7. Adverse Effect. Data for severe adverse reaction (grade
III/IV/V) were extracted from seven trials. 15 types of severe
toxicity in patients treated with gefitinib or gefitinib plus
chemoradiotherapy were assessed. The pooled RRs of all
toxicities, diarrhea, and skin toxicity both showed significant
differences for patients who received gefitinib-based therapy
(P=0.0003; P=0.03). Instead, other toxicities revealed no
differences (Table 2).
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Figure 3: OS between gefitinib and no gefitinib group in patients with advanced head and neck cancer (HR 1.07; Z=0.94; P=0.35).
Figure 4: PFS between gefitinib and no gefitinib group in patients with advanced head and neck cancer (HR 0.84; Z=1.62; P=0.11).
(a)
(b)
Figure 5: ORR between gefitinib and no gefitinib group in different patients. (a) ORR between gefitinib and no gefitinib group in patients
with advanced head and neck cancer (RR: 1.04; Z=0.52; P = 0.60). (b) ORR between gefitinib and no gefitinib group in patients with recurrent
head and neck cancer (RR: 1.29; Z=0.66; P = 0.51).
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Table 2: Adverse effects associated with gefitinib.
Adverse effect No. of studies Model RR (95%CI) P value Heterogeneity (p,I2) Conclusion
Diarrhea 6 Fixed 4.29(1.96, 9.41) 0.0003 P=0.62; I2=0% Positive
Mucositis 6 Fixed 1.20 (0.96, 1.50) 0.10 P=0.86, I2=0% Negative
Skin toxicity 6 Fixed 1.71 (1.06, 2.74) 0.03 P=0.24; I2=26% Positive
Dysphagia 4 Fixed 0.90 (0.57, 1.42) 0.65 P=0.17; I2=40% Negative
Nausea 4 Fixed 0.98 (0.47, 2.02) 0.95 P=0.55; I2=0% Negative
Vomiting 4 Fixed 1.01 (0.49, 2.10) 0.97 P=0.60; I2=0% Negative
Weight loss 3 Fixed 0.48 (0.12, 1.92) 0.30 P=0.73; I2=0% Negative
Fibrosis 2 Fixed 0.77 (0.43, 1.40) 0.40 P=1.00; I2=0% Negative
Neutropenia 2 Fixed 0.97 (0.46, 2.07) 0.94 P=0.92; I2=0% Negative
Leukopenia 2 Fixed 1.20 (0.60, 2.39) 0.60 P=0.88; I2=0% Negative
Oedema 2 Fixed 1.00 (0.55, 1.82) 0.99 P=0.96; I2=0% Negative
Xerostomia 2 Fixed 0.94 (0.41, 2.16) 0.88 P=0.60; I2=0% Negative
Fatigue 3 Fixed 0.97 (0.54, 1.72) 0.91 P=0.27; I2=24% Negative
Anemic 2 Random 1.00 (0.04, 22.86) 1.00 P=0.08; I2=67% Negative
Hemorrhage 2 Random 1.30 (0.07, 24.23) 0.86 P=0.11; I2=61% Negative
3.8. Publication Bias. There was no publication bias among
trials for ORR, OS, and PFS, according to Begg’s test (ORR:
P= 0.368; OS: P= 0.462; PFS: P=1.000) and Egger’s test (ORR:
P= 0.101; OS: P= 0.318; PFS: P= 0.693) (Figure S1).
4. Discussion
This meta-analysis provides pooled estimates of the effec-
tiveness and safety of gefitinib-based therapy in patients
with advanced HNSCC. Nevertheless, we failed to find
a statistically significant difference between gefitinib-based
regimens and traditional treatment for the OS or PFS of
patients with advanced or recurrent HNSCC. ORR displays
similar tendencies as the survival. According to NCCN
Clinical Practice Guidelines for Head and Neck Cancers [1],
approximately 30% to 40%of patientswhopresentwith early-
stage disease (stage I or II) are recommended to take single-
modality treatment with surgery or radiation therapy (RT).
Combined modality therapy is generally recommended to
the approximately 60% of patients with locally or regionally
advanced disease at diagnosis. For advanced disease, several
randomized trials [19–21] and meta-analyses [22, 23] show
remarkably improved OS, disease-free survival, and local
control when a concomitant or alternating systemic therapy
and radiation regimen are comparedwithRT alone.However,
only 30%∼40% patients can survive 5 years; thus, novel
treatment strategies are urgently needed.
The differences in the response to the treatment of
HNSCC, which had been caused by complex primary sites,
may affect the result. Bonner’s investigation [8] indicated that
locoregional control and median overall survival [HR=0.73,
95%CI (0.56-0.95), and P=0.03] were significantly increased
in patients treated with RT and cetuximab compared to RT
alone, whereas, in their secondary analyses [24] from this
trial including only patients with cancer of the larynx or
hypopharynx (n=168), researchers found that there is no
statistically significant difference between the two groups
for laryngeal preservation, laryngectomy-free survival, and
median overall survival. Therefore, future study on gefitinib
in patients with HNSCC of different primary tumors is
needed. What is more, further studies to search for genetic
variants or specific biomarkers that can contribute to identi-
fication of selected patients to benefit from gefitinib are badly
needed.
Health-related quality-of-life (QOL) issues are para-
mount in HNSCC.These tumors have a direct effect on basic
physiologic functions like the ability to chew, swallow, and
breathe and the senses such as taste, smell, hearing, even
uniquely human characteristics like appearance and voice.
For head and neck cancer-specific issues, there are three
validated and accepted measures: (1) the Functional Assess-
ment of Cancer Therapy Head and Neck module (FACT-
H&N) [25], (2) the University of Washington Quality of Life
scale (UW-QOL) [26]; and (3) the European Organization for
Research and Treatment of Cancer Quality of Life Question-
naire (EORTC-HN35) [27]. Differences exist in the methods
of evaluation of QOL in the two trials, so we did not perform
meta-analysis. Even so, QOL improvement has been proved
in gefitinib arm. Gefitinib is a small-molecule targeting
agent that specifically inhibits EGFR-tyrosine kinase, which
is usually administered as a once-daily oral tablet. This study
shows that gefitinib did not improve the survival of patients
with advanced HNSCC, but the subgroup analyses manifest
that gefitinib alone and chemotherapeutics (i.e., methotrex-
ate; methotrexate + fluorouracil) are equivalent in ORR in
patients with recurrent HNSCC. Simultaneously, gefitinib
arm may improve QOL. Hence, gefitinib may be one of the
optimal choices for recurrent patients who are refractory to
high-intensity therapy. More researches to evaluate the QOL
in HNSCC patients with gefitinib are needed.
In our meta-analysis, we found that no significant dif-
ferences exist between the two groups for most toxicity
data except for diarrhea and skin toxicity. The package
inserts of gefitinib and literature show that diarrhea and skin
toxicity are common adverse reactions, which are usually
reversible and manageable with appropriate interventions
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[28]. Heterogeneity exists in the pooled RRs of the grade 3
to 4 anemic and hemorrhage toxicity. As only two studies
reported the two toxicities, we did not undertake sensitivity
analysis.
Based on the current evidence, this meta-analysis has
several limitations. First, the study size was limited, and
too few trials were included for some subgroup analyses, so
that we cannot conduct meta-analysis for each disease stage,
such as LA or RM. Moreover, this meta-analysis included
several small sample studies. Second, some RCTs were of
poor quality; for example, they used unclear allocation con-
cealment. Third, different treatment modalities were adopted
among the studies. Fourth, primary sites of the head and neck
cancer were various in the included studies, but few studies
subdivided these lesions, leading to the failure of analyzing
them according to the specific disease sites. Fifth, we did not
conduct meta-analysis of QOL, which is an essential factor
for efficacy, because of the small number of trials and different
evaluation methodologies.
5. Conclusions
Disappointingly, benefits from gefitinib of patients with
advanced HNSCC are still negative. It cannot prolong the
OS and PFS or improve ORR, with the cost of increased
odds of skin toxicity and diarrhea. Nevertheless, for recurrent
patients, gefitinib is a promising agent, which is equivalent to
methotrexate and methotrexate + fluorouracil, and tends to
improve QOL.
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